Abstract:Large tumor suppressor (Lats) plays a critical role in maintaining cellular homeostasis and is the core to mediate Hippo growth-inhibitory signaling pathway. SUMOylation is a reversible and dynamic process that regulates a variety of cell functions. Here, we show that SUMOylation of Lats1 affects its kinase activity specifically towards Hippo signaling. Small ubiquitin-like modifier (SUMO) 1 interacts with and directly SUMOylates Lats1, whereas loss of SUMOylation pathway function disrupts Lats1 SUMOylation. Among potential SUMOylation sites on hLats1, K751 and K830 are conversed and essential for maintaining the transcriptional output of Hippo signaling, whereas K751 mutation more significantly abolishes SUMO1-induced Lats1 SUMOylation than K830 mutation. Though Lats1 SUMOylation at K751 affects neither its subcellular distribution nor its interactions with YAP and TAZ, it significantly destabilizes the phosphorylated Lats1 (Thr1079 but not Ser909), resulting in the attenuation of Lats1 kinase activity and inhibition of Hippo signaling. Moreover, HepG2 hepatocellular carcinoma cells express significantly more SUMOylated Lats1 than LO2 normal human hepatic cells, and in HepG2 cells or HepG2 cells xenografts, Lats1 SUMOylation at K751 consistently attenuates Lats1 kinase activity and subsequently suppresses Hippo signaling, resulting in not only the promotion of cell proliferation and colony formation but also the suppression of cell apoptosis. Together, we demonstrate that Lats1 SUMOylation at K751 suppresses its kinase activity and subsequently attenuates its tumor-suppressor functions. Thus, this study provides additional insight into how Hippo signaling is regulated and highlights the potentially critical role of Lats1 SUMOylation in tumor development.

WWP2 drives the progression of gastric cancer by facilitating the ubiquitination and degradation of LATS1 protein

Cell type-dependent function of LATS1/2 in cancer cell growth

WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression

The E3 ubiquitin ligase, FBXW5, promotes the migration and invasion of gastric cancer through the dysregulation of the Hippo pathway

LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma

WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy

WWP1 As a Potential Tumor Oncogene Regulates PTEN-Akt Signaling Pathway in Human Gastric Carcinoma.

SUMOylation of Large Tumor Suppressor 1 at Lys751 Attenuates Its Kinase Activity and Tumor-Suppressor Functions

Erratum: LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction (LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction (2013) 5(6) (1650–1663), (S2211124713007213), (10.1016/j.celrep.2013.11.037))

LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP

T851I Mutation of Human Large Tumor Suppressor 1 Disrupts Its Kinase Activity and Tumor-Suppressor Functions.

Role of LATS1/2 in Prognosis of Advanced Gastric Cancer and Its Relationship with the Tumor Immune Microenvironment

DUB1 Suppresses Hippo Signaling Via Modulating TAZ Protein in Gastric Cancer

LATS1 K751 Acetylation Blocks Activation of Hippo Signalling and Switches LATS1 from a Tumor Suppressor to an Oncoprotein

Lats2, a Putative Tumor Suppressor, Inhibits G1/S Transition

BZW2 promotes malignant progression in lung adenocarcinoma through enhancing the ubiquitination and degradation of GSK3β

USP12 facilitates gastric cancer progression via stabilizing YAP

Deubiquitylase USP9X Suppresses Tumorigenesis by Stabilizing Large Tumor Suppressor Kinase 2 (LATS2) in the Hippo Pathway.

LATS2 induced by TNF-alpha and inhibited cell proliferation and invasion by phosphorylating YAP in oral squamous cell carcinoma.

The long noncoding RNA ELFN1-AS1 promotes gastric cancer growth and metastasis by interacting with TAOK1 to inhibit the Hippo signaling pathway

DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer